Find a Cancer Clinical Trial for Your Child
Memorial Sloan Kettering conducts hundreds of clinical trials to improve care for people with many types of cancer. This includes more than 100 studies for children, teens, and young adults. Use this tool to browse our list of open clinical trials for young people. Each listing explains the purpose of the trial, who is eligible, and how to get more information.
New clinical trials are always opening. For more information and to find out about our latest studies, call 833-675-5437 or email us at mskkids@mskcc.org.
Displaying 11–20 of 80 results.
-
This protocol will provide expanded access to treatment with the investigational drug L-MTP-PE for people with osteosarcoma. L-MTP-PE works by activating certain types of white blood cells, and these active white blood cells help the immune system to kill cancer cells. L-MTP-PE is given intravenously (by vein).
-
The overall goal of this study is to see if adding inotuzumab ozogamicin to standard chemotherapy maintains or improves treatment effectiveness in young patients with high-risk B cell acute lymphoblastic leukemia (B-ALL). Inotuzumab ozogamicin contains an antibody (inotuzumab) linked to a type of chemotherapy (calicheamicin). Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them.
-
Cushing's syndrome occurs when the adrenal glands produce too much of the "stress hormone" known as cortisol. This can be caused by a tumor which develops in the pituitary gland and secretes a hormone called adrenocorticotropic hormone (ACTH). Cushing's syndrome can also be caused by an ACTH-secreting tumor elsewhere in the body, or by a tumor in the adrenal glands that makes cortisol.
-
The purpose of this study is to see how treatment for retinoblastoma in one eye affects quality of life in survivors of this cancer who had chemotherapy (injected into the eye) or surgery to remove the eye. Researchers will ask participants about their physical and emotional health and ability to perform daily activities. They want to determine if there are any differences between these treatments with respect to their effect on quality of life. It is hoped that this information will help doctors provide better care for children with retinoblastoma in the future and better follow-up care for survivors of this cancer.
-
This study is evaluating the safety and effectiveness of combination chemotherapy, surgery, and radiation therapy in children and young adults with newly diagnosed stage II-IV diffuse anaplastic Wilms' tumors (DAWT) or favorable histology Wilms' tumors (FHWT) that have come back (relapsed).
-
The purpose of this study is to find the highest dose of the investigational drug PC14586 that can be given in patients with solid tumors that came back or continue to grow despite prior therapy and contain a mutation in the TP53 gene. The p53 protein produced by this gene normally tells cells when to stop dividing, but when TP53 is altered (mutated), cancer may result.
-
Daunorubicin, cytarabine, and gemtuzumab ozogamicin are different chemotherapy drugs used to treat acute myeloid leukemia (AML). CPX-351 is made up of daunorubicin and cytarabine. It is created in a way that makes the drugs stay in the bone marrow longer and could be less likely to cause heart problems than traditional anthracycline drugs, a common class of chemotherapy drugs used in cancer care.
-
The purpose of this study is to assess the safety and effectiveness of combining a "bivalent" vaccine with two agents that stimulate the immune system: a sugar called beta-glucan and a medication called GM-CSF. The treatment is designed to prevent the relapse of patients with high-risk neuroblastoma that is in complete remission. This bivalent vaccine works by stimulating an immune response against two different antigens, which are markers on the surface of a cell.
-
Studies have shown that patients with newly diagnosed localized non-germinomatous germ cell tumors (NGGCT) of the brain or spinal cord whose disease responds well to chemotherapy before receiving radiation therapy are more likely to be free of the disease for a longer time than patients in whom chemotherapy is less effective.
-
The purpose of this study is to find the highest dose of the investigational treatment UCART22 that can be given safely in children and young adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or continued to grow despite treatment. UCART22 is a form of CAR T-cell therapy. It is made from white blood cells (T cells) from healthy donors. The T cells are genetically modified in a laboratory to identify and destroy cancer cells containing a protein called CD22.